Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis

OBJECTIVE: To assess long‐term efficacy and safety of guselkumab, an interleukin‐23 p19 subunit (IL‐23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III DISCOVER‐2 trial. METHODS: In the DISCOVER‐2 trial, patients with active PsA (≥5 swollen joints and ≥5 tender joi...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B., Rahman, Proton, Gottlieb, Alice B., Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Jiang, Yusang, Sheng, Shihong, Shawi, May, Chakravarty, Soumya D., van der Heijde, Désirée, Mease, Philip J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305108/
https://www.ncbi.nlm.nih.gov/pubmed/34719872
http://dx.doi.org/10.1002/art.42010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305108/
https://www.ncbi.nlm.nih.gov/pubmed/34719872
http://dx.doi.org/10.1002/art.42010

Ejemplares similares